• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Jamie P. Dwyer, MD

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
0 out of 5 Patient Rating

Languages Spoken: English

Specialties

  • Nephrology & Hypertension

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Nephrology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Nephrology)

Academic Locations

School of Medicine

801-581-6709

30 N 1900 E
Nephrology, RM 4R312
Salt Lake City, UT  84132

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor (Clinical)
Academic Divisions Nephrology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Nephrology)

Education History

Research Fellow Vanderbilt University
Nephrology
Chief Fellow, 2006
Fellowship Vanderbilt University
Nephrology/Hypertension
Clinical Fellow, 2005
Residency Mayo Clinic
Internal Medicine
Chief Resident, 2004
Residency Mayo Clinic
Internal Medicine
Resident, 2003
Professional Medical Brown University School of Medicine
Medicine
M.D. with Distinction, 2000
Undergraduate Brown University
Classics: Latin
A.B., 1996
Undergraduate Brown University
Mathematics
Sc.B., 1996

Selected Publications - Journal Articles

Journal Article

  1. Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, Tidwell W, Guide A, Testani JM, Lewis JB, Dwyer JP (2021). Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. J Card Fail.
  2. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 44(8), 1805-1815.
  3. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD (2022). Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol, 6(7), 801-810.
  4. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 384(20), 1921-1930.
  5. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Daz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED Investigators (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med, 384(2), 129-139.
  6. Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, McWilliams A, Oparil S, Rahbari-Oskoui F, Rahman M, Parkulo MA, Pemu P, Raj DS, Rocco M, Soman S, Thomas G, Tuot DS, Whelton PK, Pajewski NM (2020). Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. JAMA Intern Med, 180(12), 1655-1663.
  7. Heerspink HJL, Stefnsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjstrm CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020). Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 383(15), 1436-1446.
  8. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Grriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjstrm CD, Langkilde AM, Heerspink HJL (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant, 35(10), 1700-1711.
  9. Burgner A, Ikizler TA, Dwyer JP (2020). COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis. Clin J Am Soc Nephrol, 15(5), 720-722.
  10. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators (2019). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant, 35(2), 274-282.
  11. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol, 7(8), 606-617.
  12. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2019). Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 139(22), 2528-2536.
  13. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 139(22), 2516-2527.
  14. Rahimi K, Canoy D, Nazarzadeh M, Salimi-Khorshidi G, Woodward M, Teo K, Davis BR, Chalmers J, Pepine CJ, Blood Pressure Lowering Treatment Trialists Collaboration (2019). Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). BMJ Open, 9(5), e028698.
  15. Waguespack DR, Dwyer JP (2018). Assessment of Blood Pressure: Techniques and Implications From Clinical Trials. Adv Chronic Kidney Dis, 26(2), 87-91.
  16. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP, EPIC Study Group (2019). Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 380(8), 729-740.
  17. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA, Chronic Kidney Disease Epidemiology Collaboration (2019). Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol, 7(2), 128-139.
  18. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARETIMI 58 Investigators (2018). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 380(4), 347-357.
  19. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee and Investigators (2018). Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 139(3), 366-375.
  20. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee Investigators (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, 392(10161), 2269-2279.
  21. Nogid B, Lacy MK, Jacobs M, Bruss J, Dwyer J (2018). Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials. Pharmacotherapy, 38(10), 990-998.
  22. Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol M (2018). Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. PLoS One, 13(9), e0203305.
  23. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIATIMI 61 Steering Committee and Investigators (2018). Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med, 379(12), 1107-1117.
  24. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int, 93(6), 1397-1408.
  25. Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, Oparil S, Beddhu S, Dwyer JP, Gren LH, Kostis WJ, Lioudis M, Pisoni R, Rosendorff C, Haley WE, SPRINT Research Group (2018). Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 71(6), 1064-1074.
  26. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM, SPRINT Research Group (2017). Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis, 71(3), 352-361.
  27. Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJL (2017). Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects? Clin J Am Soc Nephrol, 12(10), 1595-1600.
  28. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Group (2017). Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med, 377(8), 733-744.
  29. Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Group (2017). A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney Int Rep, 2(5), 800-810.
  30. Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral S (2016). Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodial Int, 21(2), 243-249.
  31. Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, Niecestro R, Hunsicker LG, Greene T, Lewis JB, Dwyer JP (2017). The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
. Clin Nephrol, 87 (2017)(3), 124-133.
  32. Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, Fine LJ, Goff DC Jr, Haley WE, Krousel-Wood M, McWilliams A, Rifkin DE, Slinin Y, Taylor A, Townsend R, Wall B, Wright JT, Rahman M (2016). Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension, 69(1), 42-50.
  33. van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink HL (2016). Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes Obes Metab, 18(11), 1120-1127.
  34. Dwyer JP (2016). We Give Too Much Intravenous Iron. Semin Dial, 29(4), 309-11.
  35. Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Group (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 86(13), 1208-16.
  36. Chang TI, Evans G, Cheung AK, Cushman WC, Diamond MJ, Dwyer JP, Huan Y, Kitzman D, Kostis JB, Oparil S, Rastogi A, Roumie CL, Sahay R, Stafford RS, Taylor AA, Wright JT Jr, Chertow GM, SPRINT Study Research Group (2016). Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension, 67(3), 550-5.
  37. Schievink B, Krpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink HJ (2015). Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab, 18(1), 64-71.
  38. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373(22), 2103-16.
  39. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study Group (2015). Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol, 26(10), 2578-87.
  40. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group (2015). The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis, 66(3), 479-88.
  41. Rodby RA, Umanath K, Niecestro R, Bond TC, Sika M, Lewis J, Dwyer JP, Collaborative Study Group (2015). Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs R D, 15(3), 271-9.
  42. Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP, Collaborative Study Group (2014). Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res, 15(3), 545-50.
  43. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group (2014). Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol, 26(2), 493-503.
  44. Coffin ST, Waguespack DR, Haglund NA, Maltais S, Dwyer JP, Keebler ME (2015). Kidney dysfunction and left ventricular assist device support: a comprehensive perioperative review. Cardiorenal Med, 5(1), 48-60.
  45. Dwyer JP, Greco BA, Umanath K, Packham D, Fox JW, Peterson R, Broome BR, Greene LE, Sika M, Lewis JB (2014). Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron, 129(1), 22-8.
  46. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D (2014). Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis, 64(5), 714-22.
  47. Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer JP (2014). Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. Expert Rev Clin Pharmacol, 7(6), 705-10.
  48. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, SPRINT Study Research Group (2014). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials, 11(5), 532-46.
  49. Haglund NA, Feurer ID, Dwyer JP, Stulak JM, DiSalvo TG, Keebler ME, Schlendorf KH, Wigger MA, Maltais S (2014). Does renal dysfunction and method of bridging support influence heart transplant graft survival? Ann Thorac Surg, 98(3), 835-41.
  50. Umanath K, Lewis JB, Dwyer JP (2013). Optimizing blood pressure control in patients with nondiabetic glomerular disease. Adv Chronic Kidney Dis, 21(2), 200-4.
  51. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D (2013). Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis, 63(2), 244-50.
  52. Hartle PM, Carlo ME, Dwyer JP, Fogo AB (2013). AKI in an HIV patient. J Am Soc Nephrol, 24(8), 1204-8.
  53. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013). Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis, 61(5), 759-66.
  54. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2012). Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int, 17(1), 67-74.
  55. Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer JP (2012). In-center thrombolysis for clotted AV access: a cohort review. Semin Dial, 26(1), 124-9.
  56. Elliott MR, Soto Soto JM, Haley WE, Fitzpatrick PM, Dwyer JP (2012). Labile hypertension: characteristics of a referred cohort. Clin Exp Hypertens, 35(3), 207-12.
  57. Dwyer JP, Lewis JB (2012). Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. Med Clin North Am, 97(1), 53-8.
  58. Umanath K, Niecestro R, Lewis JB, Dwyer JP (2019). Ferric citrate: a novel phosphate-binding agent. Expert Rev Endocrinol Metab, 8(1), 13-19.
  59. Fatima H, Siew ED, Dwyer JP, Paueksakon P (2012). Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis. Clin Kidney J, 5(6), 587-90.
  60. Siew ED, Ikizler TA, Matheny ME, Shi Y, Schildcrout JS, Danciu I, Dwyer JP, Srichai M, Hung AM, Smith JP, Peterson JF (2012). Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clin J Am Soc Nephrol, 7(5), 712-9.
  61. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB (2011). Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med, 2(1), 1-10.
  62. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC, Collaborative Study Group (2011). Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 123-30.
  63. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group (2011). Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 131-6.
  64. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2011). Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis, 59(1), 75-83.
  65. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Collaborative Study Group (2012). The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract, 121(1-2), c25-9.
  66. Dwyer JP, Lewis JB (2011). Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important? Am J Kidney Dis, 58(5), 700-3.
  67. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis, 58(5), 729-36.
  68. Basford AW, Lewis J, Dwyer JP, Fogo AB (2011). Membranous nephropathy with crescents. J Am Soc Nephrol, 22(10), 1804-8.
  69. Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers Heerspink H, Dwyer JP, Atkins RC, Lewis J, Collaborative Study Group (2011). Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron Clin Pract, 118(4), c331-8.
  70. Elliott MR, Cortese C, Moreno-Aspitia A, Dwyer JP (2009). Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis, 55(6), 1136-41.
  71. Dwyer JP, Greco BA, Lewis JB (2009). Evaluation of renal artery stenosis in dialysis patients. Semin Dial, 22(5), 519-23.
  72. Bridges MD, St Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM (2009). High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR Am J Roentgenol, 192(6), 1538-43.
  73. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC (2009). Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read, 19(3), 114-21.
  74. Umana IE, Dwyer JP (2009). Vicarious contrast excretion by the gallbladder in contrast nephropathy. Kidney Int, 75(4), 446.
  75. Lette F, Dwyer JP (2008). The fluid craze. Lancet, 372(9641), 782-4.
  76. Dwyer JP, Yates KM, Sumner EL, Stone WJ, Wang Y, Koury MJ, Fogo AB, Zent R (2007). Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. Clin Nephrol, 67(3), 176-81.

Conference Proceedings

  1. Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR, Conference Participants (2018). Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, United States, 93(6), 1281-1292.

Editorial

  1. Umanath K, Burgner A, Lewis JB, Dwyer JP (2014). Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee. Am J Kidney Dis, 63(6), 895-9.

Letter

  1. McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, CARE Study Group (2019). Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. [Letter to the editor]. N Engl J Med, 380(8), 791-793.
  2. Choma DP, Cavanaugh KL, Dwyer JP (2010). Is it always wrong to perform futile CPR? [Letter to the editor]. N Engl J Med, 362(21), 2036; author reply 2036-7.
  3. Dwyer JP, Cohen MD (2005). Interns' work hours. [Letter to the editor]. N Engl J Med, 352(7), 726-8; author reply 726-8.

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube
  • Instagram

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2022 University of Utah Health